Transcranial Direct Current Stimulation Safe, Effective for Tardive Dyskinesia
By Lori Solomon HealthDay Reporter
MONDAY, Nov. 18, 2024 -- Transcranial direct current stimulation (tDCS) may be an effective and safe treatment for improving the facial-oral motor symptoms of tardive dyskinesia (TD) in chronically hospitalized patients with schizophrenia, according to a study published online in the October issue of Clinical Neurophysiology.
Xiaoli Lyu, from the Teaching Hospital of Yangzhou University in China, and colleagues evaluated the efficacy and safety of tDCS in long-term hospitalized patients with chronic schizophrenia and TD. The analysis included 64 patients randomly assigned to active (35 participants) or sham (29 participants) treatment (15 30-minute sessions).
The researchers found that patients in the active group showed a significant reduction in both the total Abnormal Involuntary Movements Scale (AIMS) score and the facial-oral subscore. In the active group, a significant AIMS total score improvement of ≥30 percent was achieved in half of patients versus 8.3 percent in the sham group. The Positive and Negative Syndrome Scale and the Scale for the Assessment of Negative Symptoms scores did not significantly differ between the treatment groups. The occurrence of the reported adverse effect of tingling sensation differed significantly between the groups.
"The results of our study are expected to provide a novel perspective for the treatment of patients with chronic schizophrenia complicated by TD in clinical settings," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Mental Health Hospitalizations Common in Adults With Autism
WEDNESDAY, July 23, 2025 -- Mental health hospitalizations are more common among adults with autism, with more than one-third of all admissions tied to mental health conditions...
Chronic Exposure to Systemic Inflammation May Increase Risk for Affective Disorders
THURSDAY, July 3, 2025 -- For individuals with specific autoimmune conditions, there appears to be an increased risk for affective disorders, according to a study published online...
Weekly LYN-005 Provides Sustained Risperidone Release in Schizophrenia
WEDNESDAY, June 18, 2025 -- For patients with schizophrenia, weekly LYN-005 provides sustained release of risperidone at therapeutic concentrations, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.